GGrantIndex
Sort

25,944 grants matching neurodegeneration

Plasma brain-derived tau: a novel Alzheimer’s disease-type neurodegeneration biomarker with potential to complete the AT(N) scheme in blood

$5,693,957
Thomas K Karikari · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · AG

Dominantly Inherited Alzheimer Network

$5,643,579
Randall J Bateman · Washington University · U19 · FY2023 · AG

Sphingolipid Biology of Neurodegeneration

$5,572,752
Richard Proia · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK

Frontotemporal Dementia: Genes, Images, and Emotions

$5,553,559
Maria Luisa Gorno Tempini · University Of California, San Francisco · P01 · FY2023 · AG

Roles of Gray Matter Brain Aging and Small Vessel Disease in AD Pathophysiology

$5,546,075
Howard J Aizenstein · University Of Pittsburgh At Pittsburgh · RF1 · FY2021 · AG

Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects

$5,526,538
John Didsbury · T3d Therapeutics, Inc. · R01 · FY2022 · AG

Frontotemporal Dementia: Genes, Images, and Emotions

$5,506,891
Maria Luisa Gorno Tempini · University Of California, San Francisco · P01 · FY2025 · AG

Frontotemporal Dementia: Genes, Images, and Emotions

$5,446,505
Maria Luisa Gorno Tempini · University Of California, San Francisco · P01 · FY2024 · AG

Blood amyloid, tau, and neurodegeneration biomarkers and prediction of clinical onset, cognitive decline, and dementia diagnosis

$5,409,374
Randall J Bateman · Washington University · R01 · FY2025 · AG

FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.

$5,308,961
Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2025 · AG

Epidemiology of Age-related Dementia, Mild Cognitive Impairment and Brain Pathology in a Multiethnic Cohort of Oldest-Old

$5,224,302
Rachel A Whitmer · University Of California At Davis · R01 · FY2024 · AG

Epidemiology of Age-related Dementia, Mild Cognitive Impairment and Brain Pathology in a Multiethnic Cohort of Oldest-Old

$5,187,231
Rachel A Whitmer · University Of California At Davis · R01 · FY2023 · AG

Blood amyloid, tau, and neurodegeneration biomarkers and prediction of clinical onset, cognitive decline, and dementia diagnosis

$5,175,354
Randall J Bateman · Washington University · R01 · FY2024 · AG

Genetic and epigenetic regulation of retinal development, aging and evolution

$5,173,977
Anand Swaroop · National Eye Institute · ZIA · FY2022 · EY

The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias (ADRD)

$5,172,719
Amy J. Kind · University Of Wisconsin-Madison · R01 · FY2025 · AG

Epidemiology of Age-related Dementia, Mild Cognitive Impairment and Brain Pathology in a Multiethnic Cohort of Oldest-Old

$5,163,761
Rachel A Whitmer · University Of California At Davis · R01 · FY2022 · AG

Biological predictors of brain aging trajectories

$5,127,088
Joel H Kramer · University Of California, San Francisco · RF1 · FY2020 · AG

ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE

$5,116,455
Reisa A. Sperling · University Of California, San Diego · U19 · FY2014 · AG

Epidemiology of Age-related Dementia, Mild Cognitive Impairment and Brain Pathology in Cohort of Oldest-Old

$5,105,538
Rachel A Whitmer · University Of California At Davis · R01 · FY2025 · AG

Mechanisms of inherited neurodegenerative diseases

$5,084,626
Michael Ward · National Institute Of Neurological Disorders And Stroke · ZIA · FY2025 · NS

Multimodal MRI in Multiple Sclerosis

$5,061,016
Daniel Reich · National Institute Of Neurological Disorders And Stroke · ZIA · FY2021 · NS

NDC for the Optical Control of Biological Function

$5,039,000
Ehud Isacoff · University Of California Berkeley · PN2 · FY2010 · EY

APOE in the Predisposition to, Protection from and Prevention of Alzheimer's Disease

$5,031,927
Eric M Reiman · Banner Health · R01 · FY2023 · AG

Clinical & biological signatures of post-traumatic neurodegeneration: Leveraging the TBI Model Systems of Care to accelerate in vivo diagnosis of the late effects of TBI (LETBI)

$5,005,696
Kristen Dams-O'Connor · Icahn School Of Medicine At Mount Sinai · RF1 · FY2022 · NS

NDC for the Optical Control of Biological Function

$5,000,000
Ehud Isacoff · University Of California Berkeley · PN2 · FY2012 · EY